Dexetimide

Identification

Name
Dexetimide
Accession Number
DB08997
Type
Small Molecule
Groups
Withdrawn
Description

A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
43477QYX3D
CAS number
21888-98-2
Weight
Average: 362.4647
Monoisotopic: 362.199428086
Chemical Formula
C23H26N2O2
InChI Key
LQQIVYSCPWCSSD-HSZRJFAPSA-N
InChI
InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)/t23-/m1/s1
IUPAC Name
(3S)-3-(1-benzylpiperidin-4-yl)-6-hydroxy-3-phenyl-2,3,4,5-tetrahydropyridin-2-one
SMILES
OC1=NC(=O)[C@@](CC1)(C1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1,10-PhenanthrolineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Aclidinium.
AgmatineThe risk or severity of adverse effects can be increased when Agmatine is combined with Dexetimide.
Ajulemic acidThe risk or severity of Tachycardia and drowsiness can be increased when Dexetimide is combined with Ajulemic acid.
AlcuroniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alcuronium.
AlfentanilThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alphacetylmethadol.
AlphaprodineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alphaprodine.
Aluminum sulfateThe therapeutic efficacy of Aluminum sulfate can be decreased when used in combination with Dexetimide.
AmantadineThe risk or severity of adverse effects can be increased when Amantadine is combined with Dexetimide.
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,125,578.

General References
Not Available
External Links
PubChem Compound
30843
PubChem Substance
310264958
ChemSpider
28615
ChEBI
135531
ChEMBL
CHEMBL1908364
Wikipedia
Dexetimide
ATC Codes
N04AA08 — Dexetimide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)299-301.5U.S. Patent 3,125,578.
Predicted Properties
PropertyValueSource
Water Solubility0.00505 mg/mLALOGPS
logP3.75ALOGPS
logP2.85ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)7.67ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.9 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.66 m3·mol-1ChemAxon
Polarizability40.55 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Phenylmethylamines / Benzylamines / Tetrahydropyridines / Aralkylamines / Trialkylamines / N-acylimines / Lactims / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds
show 4 more
Substituents
N-benzylpiperidine / Benzylamine / Phenylmethylamine / Aralkylamine / Tetrahydropyridine / Monocyclic benzene moiety / Hydropyridine / Benzenoid / Amino acid or derivatives / Tertiary amine
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 16, 2014 13:39 / Updated on November 02, 2018 06:57